A- A A+

Yu-Wen Hu (胡育文)

  • 2875-7270
Yu-Wen Hu(胡育文)

簡介

學歷 國立陽明大學 醫學系 醫學士
經歷 現職:
  1. - 迄今 臺北榮民總醫院 腫瘤醫學部 放射腫瘤科 主治醫師
  2. - 迄今 國立陽明大學 醫學系 兼任講師
經歷:
  1. - 臺北榮民總醫院 腫瘤醫學部 住院總醫師
醫療專長
  1. 鼻咽癌、頭頸癌、婦癌、泌尿道腫瘤、肺癌等放射治療
證照
  1. 中華民國放射腫瘤科專科醫師

著作

PubMed

  1. Lin ST, Wang TH, Shiau CY, Liu YM, Chen TJ*, Hu YW*.  整合多套放射腫瘤與醫療資訊系統以實現病歷電子化 Integration of Multiple Radiation Oncology and Health Information Systems to Implement Computerization of Medical Records. Therapeutic Radiology and Oncology 2018 Mar; 25(1): 21-32. (IF: -)

  2. Wang TH*, Hu YW*.  Benefit of Adjuvant Therapy in Postoperative Early-Stage Small-Cell Lung Cancer: Is There Sufficient Evidence? J Clin Oncol 2017 Jan; 35(1): 117. Epub 2016 Oct. (IF: 24.008; Oncology 5/217)

  3. Lai TY, Hu YW*.  Neoadjuvant Therapy in Resectable Pancreatic Cancer: Immortal Time Bias and Its Correction. J Clin Oncol 2017 May; 35(14): 1623. Epub 2017 Jan. (IF: 24.008; Oncology 5/217)

  4. Hu YW.  Real-World Role of Adjuvant Chemotherapy in Bladder Cancer. J Clin Oncol 2016 Sep; 34(26): 3224. (IF: 20.982; Oncology 5/213)

  5. Hu YW.  Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016; 69: 50-7. Eur Urol 2016 Dec; 70(6): e158. (IF: 14.976; Urology & Nephrology 1/77)

  6. Teng CJ, Hu YW, Chen SC, Yeh CM, Chiang HL, Chen TJ, Liu CJ.  Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nation-Wide Population-Based Study. J Natl Cancer Inst 2015 Nov; 108(2): djv314. (IF: 11.370; Oncology 9/213)

  7. Hu YW*.  Statins and the Risk of Cirrhosis in Chronic Hepatitis B Patients. Am J Gastroenterol 2016 Nov; 111(11): 1655. (IF: 10.383; Gastroenterology & Hepatology 6/79)

  8. Hu YW.  Chinese Herbal Medicine Use and Risk of End-Stage Renal Disease in Patients with Chronic Kidney Disease: Is There An Immortal Time Bias? Kidney Int 2016 Jul; 90(1): 227-8. (IF: 7.683; Urology & Nephrology 4/77)

  9. Chen KT, Hu YW.  Letter: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There An Immortal Time Bias? J Nucl Med 2016 Aug; 57(8): 1324. (IF: 5.849; Radiology, Nuclear Medicine & Medical Imaging 3/124)

  10. Lee PC, Hu YW, Hu LY, Chen SC, Chien SH, Shen CC, Yeh CM, Chen CC, Lin HC, Yen SH, Tzeng CH, Chen TJ, Liu CJ*.  Risk of Cancer in Patients with Cholecystitis: A Nation-Wide Population-Based Study. Am J Med 2015 Feb; 128(2): 185-91. (IF: 5.610; Medicine, General & Internal 14/155)

  11. Hu YW.  Statins and the Risk of Pancreatic Cancer in Type 2 Diabetic Patients: Immortal Time Bias in Survival Analysis? Int J Cancer 2016 Jul; 139(1): 232. (IF: 5.531; Oncology 29/213)

  12. Lai TY, Wang TH, Liu CJ, Chao TF, Chen TJ, Hu YW*.  Risk Factors for Osteonecrosis of the Jaw in Oral Cancer Patients after surgery and Eventual Adjuvant Treatment: The Potential Role of Chemotherapy. Radiother Oncol 2017 Jun; 123(3): 406-11. Epub 2017 May. (IF: 4.328; Radiology, Nuclear Medicine & Medical Imaging 13/126; Oncology 58/217)

  13. Su VY, Liu CJ, Chen YM, Chou TY, Chen TJ, Yen SH, Chiou TJ, Liu JH, Hu YW*.  Risk of Second Primary Malignancies in Lung Cancer Survivors - the Influence of Different Treatments. Target Oncol 2017 Apr; 12(2): 219-27. Epub 2016 Oct. (IF: 3.438; Oncology 87/217)

  14. Wang TH, Liu CJ, Chao TF, Chen TJ, Hu YW*.  Risk Factors for and the role of Dental Extractions in Osteoradionecrosis of the Jaws: A National-Based Cohort Study. Head Neck 2017 Jul; 39(7): 1313-21. Epub 2017 Mar. (IF: 3.376; Otorhinolaryngology 1/42; Surgery 34/196)

  15. Chiang CL, Hu YW, Wu CH, Chen YT, Liu CJ, Luo YH, Chen YM, Chen TJ, Su KC, Chou KT.  Spectrum of Cancer Risk Among Taiwanese with Chronic Obstructive Pulmonary Disease. Int J Clin Oncol 2016 Oct; 21(5): 1014-20. (IF: 2.064; Oncology 156/217)